Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Safety and Efficacy of Underwater Endoscopic Mucosal Resection for Type I Gastric Neuroendocrine Tumors Measuring 5-9 mm (POEM)

22. juli 2026 opdateret af: Mohan Ramchandani, Asian Institute of Gastroenterology, India

Safety and Efficacy of Underwater Endoscopic Mucosal Resection for Type I Gastric Neuroendocrine Tumors Measuring 5-9 mm: A Prospective Single-Centre Cohort Study

Study objectives:

Primary objective:

1.To determine the histologic R0 resection rate of UEMR for type I gastric NETs measuring 5-9 mm.

Secondary objectives:

To evaluate:

  1. En bloc resection rate
  2. Immediate and delayed adverse events
  3. Procedure time
  4. Histologic quality of resection (deep and lateral margins)
  5. Residual disease at resection scar on surveillance endoscopy oMetachronous gastric NETs during follow-up

Studieoversigt

Status

Rekruttering

Detaljeret beskrivelse

Study design This is a prospective, single-centre, single-arm cohort study evaluating UEMR for type I gastric NETs. Outcomes will be assessed at the lesion level, with statistical methods accounting for clustering of multiple lesions within individual patients.

Study population Inclusion criteria Patient-level

  1. Age ≥18 years
  2. Fit for endoscopic therapy and sedation
  3. Written informed consent Lesion-level

3.Endoscopically visible gastric neuroendocrine tumor 4.Size 5-9 mm (endoscopic estimation) 5.Clinical and/or histologic features consistent with type I gastric NET 6.No endoscopic features suggestive of deep invasion 7.Technically amenable to snare resection Exclusion criteria

Lesion-level

  1. Lesions <5 mm (managed with surveillance in routine practice)
  2. Lesions ≥10 mm
  3. Type II or type III gastric NET
  4. Evidence of muscularis propria invasion on EUS
  5. Distant metastasis or nodal disease on DOTANOC PET-CT
  6. Prior attempted resection at the same site with significant fibrosis
  7. Non-lifting lesion due to scarring

Patient-level

  1. Uncorrectable coagulopathy
  2. Inability to manage antithrombotic therapy as per guidelines
  3. Pregnancy
  4. Inability to provide informed consent

Pre-procedure evaluation

  1. Detailed clinical assessment and laboratory work-up as per institutional protocol
  2. Endoscopic documentation of:
  3. Lesion size, location, morphology
  4. Number of lesions
  5. Background mucosal atrophy
  6. EUS performed for lesions ≥8 mm, atypical morphology, or suspected deeper invasion
  7. DOTANOC PET-CT performed where clinically indicated to exclude metastatic disease

Intervention: Underwater EMR technique

  1. Standard diagnostic gastroscope
  2. Minimal insufflation followed by complete deflation of the gastric lumen
  3. Lumen filled with normal saline to achieve complete submersion of the lesion
  4. Optional marking for flat or ill-defined lesions
  5. Snare capture with a 1-2 mm margin under water
  6. Resection using standardized electrosurgical settings
  7. Defect management (clips or coagulation) at endoscopist discretion
  8. Retrieval of intact specimen
  9. Specimen orientation and pinning on cork for histopathologic assessment

Histopathologic assessment:

All specimens will be evaluated by experienced gastrointestinal pathologists.

Reported parameters:

  1. Tumor size
  2. Tumor grade and Ki-67 index
  3. Depth of invasion
  4. Lateral and vertical margins
  5. Lymphovascular invasion
  6. Resection status classified as:
  7. R0: negative lateral and vertical margins
  8. R1: microscopic margin positivity
  9. Rx: indeterminate margins

Outcome measures Primary outcome

  1. R0 resection rate per lesion Secondary outcomes
  2. En bloc resection rate
  3. Immediate bleeding (requiring endoscopic hemostasis)
  4. Delayed bleeding (within 14 days requiring medical attention)
  5. Perforation
  6. Procedure time (scope insertion to removal)
  7. Residual disease at scar on surveillance endoscopy (3-6 months)
  8. Metachronous lesions during follow-up

Follow-up protocol

  1. Clinical follow-up at 24-72 hours and at 14 days
  2. Surveillance endoscopy at 3-6 months post-resection
  3. Further surveillance as per institutional protocol for type I gastric NETs

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

60

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Telangana
      • Hyderabad, Telangana, Indien, 500082
        • Rekruttering
        • Asian Institute of Gastroenterology/AIG Hospitals
        • Kontakt:
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

Patient-level

  • Age ≥18 years
  • Fit for endoscopic therapy and sedation
  • Written informed consent

Exclusion Criteria:

Lesion-level

  • Endoscopically visible gastric neuroendocrine tumor
  • Size 5-9 mm (endoscopic estimation)
  • Clinical and/or histologic features consistent with type I gastric NET
  • No endoscopic features suggestive of deep invasion
  • Technically amenable to snare resection

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Diagnostisk
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Andet: Type I Gastric Neuro Endocrine tumour
Lesion should be less than 10mm size
  • Standard diagnostic gastroscope
  • Minimal insufflation followed by complete deflation of the gastric lumen
  • Lumen filled with normal saline to achieve complete submersion of the lesion
  • Optional marking for flat or ill-defined lesions
  • Snare capture with a 1-2 mm margin under water
  • Resection using standardized electrosurgical settings
  • Defect management (clips or coagulation) at endoscopist discretion
  • Retrieval of intact specimen
  • Specimen orientation and pinning on cork for histopathologic assessment
Andre navne:
  • EMRUW

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
• To determine the histologic R0 resection rate of UEMR for type I gastric NETs measuring 5-9 mm.
Tidsramme: 3 months
No recurrence after 3 months of procedure
3 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Immediate and delayed adverse events
Tidsramme: 24 hours
To check any possible adverse events post procedure
24 hours
Procedure time
Tidsramme: 30 minutes
To calculate the exact time of procedure
30 minutes
Histologic quality of resection (deep and lateral margins)
Tidsramme: 5 days
To check the depth of invasion of the tumour
5 days

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Zaheer Dr Nabi, MD, AIG Hospitals
  • Studiestol: Mohan Dr Ramchandani, MD, AIG Hospitals

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

17. juli 2026

Primær færdiggørelse (Anslået)

10. november 2026

Studieafslutning (Anslået)

30. december 2026

Datoer for studieregistrering

Først indsendt

22. juli 2026

Først indsendt, der opfyldte QC-kriterier

22. juli 2026

Først opslået (Faktiske)

27. juli 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

27. juli 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

22. juli 2026

Sidst verificeret

1. juli 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • EMR01

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner